Prevention of human adenocarcinoma with CpG-ODN in a mouse model

Oncology Letters

Volumn 4, Issue 5, 2012, Pages 1061-1063

  Wright, Stephen E ^a,b,c   Rewers Felkins, Kathleen A ^a   Chowdhury, Nazrul I ^a   Ahmed, Jewel ^a   Srivastava, Sanjay K ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b School of Medicine   (United States)

^c Harrington Cancer Center   (United States)

Author keywords

Cancer; CpG ODNs; Innate immune system; NOD SCID mice

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CANCER GROWTH; CELL FUNCTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; INNATE IMMUNITY; NONHUMAN; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; T LYMPHOCYTE; TUMOR GROWTH;

EID: 84866084845     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.849     Document Type: Article

References (25)

1. Higgins RJ, McKisic M, Dickinson PJ, et al: Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol Immunother 53: 338-344, 2004.
2. Carpentier AF, Chen L, Maltonti F and Delattre JY: Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59: 5429-5432, 1999.
3. Jakob T, Walker PS, Krieg AM, Udey MC and Vogel JC: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161: 3042-3049, 1998.
4. Carpentier AF, Xie J, Mokhtari K and Delattre JY: Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6: 2469-2473, 2000.
5. Sandler AD, Chihara H, Kobayashi G, et al: CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 63: 394-399, 2003.
6. Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130, 2007.
7. Wright SE, Rewers-Felkins KA, Quinlin IS, et al: Adoptive immunotherapy of mucin1 expressing adenocarcinomas with mucin1 stimulated human peripheral blood mononuclear cells. Int J Mol Med 9: 401-404, 2002.
8. Dewan MZ, Watanabe M, Terashima K, et al: Prompt tumor formation and maintenance of constitutive NF-κB activity of multiple myeloma cells in NOD/SCID/γCnull mice. Cancer Sci 95: 564-568, 2004.
9. Beckhove P, Schütz F, Diel IJ, et al: Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice. Int J Cancer 105: 444-453, 2003.
10. Ito M, Hiramatsu H, Kobayashi K, et al: NOD/SCID/γ mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182, 2002.
11. Ballas Z, Rasmussen W and Krieg A: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157: 1840-1845, 1996.
12. Seaman WE, Sleisenger M, Eriksson E and Koo GC: Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol 138: 4539-4544, 1987.
13. Vollmer J, Weeratna R, Payette P, et al: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 34: 251-262, 2004.
14. Krieg AM, Yi AK, Matson S, et al: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
15. Krieg AM: An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med 128: 128-133, 1996.
16. Mocci S, Dalrymple SA, Nishinakamura R and Murray R: The cytokine stew and innate resistance to L. monocytogenes. Immunol Rev 158: 107-114, 1997.
17. Reynolds JV, Shou J, Choi H, Sigal R, Ziegler MM and Daly JM: The influence of natural killer cells in neuroblastoma. Arch Surg 124: 235-239, 1989.
18. Pession A, Prete A, Locatelli F, et al: Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma. Br J Cancer 78: 528-533, 1998.
19. Jones TR, Obaldia N III, Gramzinski RA, et al: Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17: 3065-3071, 1999.
20. Davis HL, Suparto II, Weeratna RR, Jumintarto, et al: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine 18: 1920-1924, 2000.
21. Weeratna RD, McCluskie MJ, Xu Y and Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18: 1755-1762, 2000.
22. Tokunaga T, Yamamoto S and Namba K: A synthetic single-stranded DNA, poly(dG, dC), induces interferon-alpha/beta and-gamma, augments natural killer activity, and suppresses tumor growth. Jpn J Cancer Res 79: 682-686, 1988.
23. Yamamoto S, Yamamoto T, Kataoka T, Kuramoto E, Yano O and Tokunaga T: Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN and augment IFN-mediated natural killer activity. J Immunol 148: 4072-4076, 1992.
24. Cohen J: IL-12 deaths: explanation and a puzzle. Science 270: 908, 1995.
25. Hemmi H, Takeuchi O, Kawai T, et al: A toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.